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Abstract Granzyme B (GzmB) is a potent apoptosis-inducing
serine protease of cytotoxic lymphocytes. Following receptor-
mediated endocytosis, GzmB is supposed to enter the cytosol
through perforin-mediated membrane disruption. We investi-
gated whether retargeting of GzmB to Lewis Y positive surface
receptors could lead to perforin-independent target cell death.
We coupled recombinant GzmB to the Lewis Y-binding anti-
body dsFv-B3. Targeting of GzmB to Lewis Y positive cells
triggered cell death with similar e⁄cacy as dsFv-B3 targeted
Pseudomonas exotoxin fragment 38 (PE38). Since GzmB was
only weakly inhibited by plasma proteins, GzmB-based immu-
noconjugates should be useful as a new class of immunotoxins
with low immunogenicity utilizing programmed cell death for
therapeutic purposes.
- 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
As a defence against viral infections and tumor growth,
programmed cell death is induced by cytotoxic T lymphocytes
(CTL) and natural killer (NK) cells in target cells expressing
foreign or altered antigens. One of the activation mechanisms
triggering apoptosis involves molecules of secretory granules,
in particular the membrane-binding perforin and granzyme B
(GzmB), and other members of the family of lymphocyte ser-
ine proteases called granzymes. GzmB is one of the most
abundant and e¡ective inducers of programmed cell death
and activates this program at multiple levels in a caspase-de-
pendent and -independent fashion [1]. The amount of GzmB
secreted during target cell recognition into the synaptic cleft is
a small fraction of the entire GzmB content of an activated
CTL and only a fraction of it presumably reaches the cytosol
during target cell attack [2,3]. The natural glycosylated GzmB
from cytotoxic granules contains mannose-6-phosphate resi-
dues and thus binds to the cation-independent mannose-6-
phosphate/insulin-like growth factor receptor (CI-MPR) on
target cells [4]. According to the current dogma, CI-MPR-
assisted endocytosis and £uid phase accumulation of GzmB
in endosomal vesicles are not su⁄cient to deliver GzmB to the
cytosol and to activate the cell death program. In addition to
GzmB the co-internalized membrane-bound perforin is re-
quired to disturb the tra⁄cking of GzmB-containing vesicles
resulting in the delivery of GzmB into the cytosol [5^8].
2. Materials and methods
2.1. Expression and puri¢cation of recombinant proteins
The cDNA for human wild-type GzmB was ampli¢ed from human
bone marrow and cloned into the pET24c(+) Escherichia coli expres-
sion vector (Novagen). We created the di¡erent recombinant GzmB
variants using standard polymerase chain reaction (PCR) and cloning
techniques. All cloned plasmid sequences were veri¢ed by sequencing
analyses. Recombinant pro-GzmB carried an N-terminal extension,
the propeptide MKH6 at the N-terminus of the mature GzmB starting
with Ile-Ile-Gly-Gly. This precursor protein was expressed, puri¢ed
and then converted to active GzmB as described for granzyme K
[9]. The concentration of all proteins was determined spectroscopically
using the appropriate extinction coe⁄cient at 280 nm. The viral serpin
cytokine response modi¢er A (CrmA) was expressed as described [10].
The cDNA plasmid in the pFLAG-1 vector was a generous gift of G.
Salvesen. The disul¢de-linked B3-R8C (dsFv-B3-R8C), an engineered
Fv fragment of the B3 antibody with the C-terminal R8CP extension,
was expressed and refolded as described [11,12]. The two components
B3-R8C and GzmB-CD8 were incubated for 2 h at room temperature
(RT) in 25 mM Na2HPO4, 25 mM KH2PO4 (pH 8.0), 2 mM ethyl-
enediamine tetraacetic acid (EDTA) and 1 mM reduced glutathione
(GSH). The pH was then shifted to 4.5, and both proteins were
dialyzed at 4‡C against 25 mM Na2HPO4, 25 mM KH2PO4 (pH
4.5), 2 mM EDTA. The free cysteine of B3-R8C was activated at
pH 8.0 and RT for 1 h by adding DTP (2,2P-dithiopyridine; Sigma)
at a 10-fold molar excess. Free DTP was removed by gel ¢ltration
(PD-10; Pharmacia). The activated B3-R8C was incubated with
GzmB-CD8 at a molar ratio of 3:1 at 20‡C in 25 mM Na2HPO4,
25 mM KH2PO4 (pH 8.1), 2 mM EDTA for 4 h. The resulting con-
jugate was separated from the uncoupled components by cation ex-
change chromatography (Poros HS) using 50 mM Tris (pH 7.4), 200
mM NaCl, 1 mM EDTA and a linear NaCl gradient from 0.2 to 2 M.
2.2. Activity of GzmB in plasma
GzmB was preincubated at RT with 5% human plasma. After 30
min CASP7C285A, a gift from G. Salvesen, was added [13]. Cleavage of
CASP7C285A was analyzed under reducing conditions by Coomassie-
stained 15% sodium dodecyl sulfate^polyacrylamide gel electrophore-
sis (SDS^PAGE). Enzymatic activity of 200 nM GzmB was measured
using the substrate Ac-IEPD-pNA (Calbiochem) at a ¢nal concentra-
tion of 250 WM in 100 mM Tris pH 8.1, 100 mM NaCl, 0.05% Triton
X-100. Absorption of the resulting cleavage product was measured at
0014-5793 / 04 / $30.00 N 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(04)00187-5
*Corresponding author. Fax: (49)-89-85783790.
E-mail address: kurschus@neuro.mpg.de (F.C. Kurschus).
1 These authors contributed equally to the paper.
Abbreviations: K1-AT, K1-antitrypsin; BSA, bovine serum albumin;
CI-MPR, cation-independent mannose-6-phosphate/insulin-like
growth factor receptor; CrmA, cytokine response modi¢er A; CTL,
cytotoxic T lymphocytes; FACS, £uorescence-activated cell sorter;
GzmB, granzyme B; NK, natural killer; PBS, phosphate-bu¡ered sa-
line; PE38, Pseudomonas exotoxin fragment 38; PI, propidium iodide;
PR3, proteinase 3; RT, room temperature; SLO, streptolysin O
FEBS 28170 15-3-04 Cyaan Magenta Geel Zwart
FEBS 28170 FEBS Letters 562 (2004) 87^92
405 nm using a Dynatech MR4000 plate reader. Incubations of 1 WM
GzmB were performed with 3 WM CrmA at 37‡C for 30 min as
described [10]. Incubations of GzmB and proteinase 3 (PR3) in human
EDTA plasma or K1-antitrypsin (K1-AT) (Sigma) were performed at
37‡C for 20 min. Remaining enzymatic activities were measured there-
after. PR3 activity (200 nM) was determined by hydrolysis of the
tetrapeptide substrate MeOSuc-AAPV-pNA (1 mM; Bachem). Back-
ground absorption of human plasma was subtracted.
2.3. Cell culture
K562 cells were grown in RPMI 1640, 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 0.1
mM 2-mercaptoethanol. SK-BR3 cells were grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM), 1% GlutaMAX I, 4.5 g/l D-glu-
cose and Na-pyruvate, 10% FBS and 0.5% gentamicin. MCF7,
MCF7casp3 and A431 cells were cultured in RPMI 1640 Dutch mod-
i¢cation (Gibco Lifescience), 10% FBS, 1% GlutaMAX, and 0.5%
gentamicin.
2.4. Short-term apoptosis induction
Adherent cells were trypsinized and resuspended in FBS-containing
medium. Cells were washed three times in serum-free medium con-
taining 0.5% bovine serum albumin (BSA) (Sigma). Apoptosis experi-
ments were performed in 100 Wl with 105 cells per well in serum-free
0.5% BSA medium. GzmB was added to the cells before the addition
of streptolysin O (SLO). SLO (25 Wg/ml) was activated in medium
containing 40 WM cysteine for 10 min at RT, diluted and freshly
added to the cells at a ¢nal concentration of 150 ng/ml. After 4^5 h
incubation adherent cells were trypsinized, washed in £uorescence-
activated cell sorter (FACS) medium (phosphate-bu¡ered saline
(PBS), 3% FBS, 0.01% NaN3) and subsequently in PBS. Cells in a
volume of 25 Wl were stained for 15 min at RT with £uorescein iso-
thiocyanate (FITC)-annexin V (Caltech) and propidium iodide (PI)
1:20 (BD-Biosciences) in binding bu¡er (BD-Biosciences), diluted
and analyzed by FACS.
2.5. Detection of Lewis Y expression
B3-R8C was labeled with TexasRed1 (Molecular Probes) via the
free cysteine. Cells were trypsinized, washed and resuspended in
FACS medium. Cells (105) were resuspended in 25 Wl of FACS me-
dium and stained with the indicated antibody dilution at 4‡C for 60
min. In parallel a live gate was de¢ned by PI staining. Then cells were
washed and analyzed by FACS.
2.6. Cytotoxic action of immunotoxins
Di¡erent cell lines were incubated with the immunoconjugates B3-
GzmB, B3-Pseudomonas exotoxin fragment 38 (PE38) or the respec-
tive unconjugated enzymes, GzmB-CD8 and E8C-PE38 [11]. Since
K562 and A431 were Lewis Y negative, the Lewis Y positive SK-
BR3, MCF7 and MCF7casp3 cells were used as targets. The cells
were cultured until they reached 20% con£uency. The immunotoxins
or control proteins were prediluted in PBS and added to the cells in
medium containing 10% FBS. After 48 h cells were harvested by
trypsinization, washed, resuspended in 10 mM HEPES/NaOH, 140
mM NaCl, 5 mM CaCl2 (pH 7.4) and stained with PI. The percentage
of viable cells was determined by FACS analysis. The data were ¢tted
according to the equation: Y= a+b/(1+10ðlogðxÞ3logðEC50ÞÞ), where a=%
surviving cells at the highest toxin concentration; b=% of surviving
cells at the lowest toxin concentration; x= toxin concentration.
3. Results and discussion
Following procedures previously described [9,14], we gener-
ated large amounts of non-glycosylated wild-type GzmB and
a catalytically inactive variant. This recombinant GzmB does
not bind to the ubiquitously expressed CI-MPR and can enter
target cells by £uid phase uptake [15]. Firstly, we tested its
apoptosis-inducing potential in cell culture, using K562 cells
as targets and sublytic concentrations of SLO as a perforin
substitute. After 5 h of incubation with SLO and GzmB, we
observed annexin V binding to the cellular membrane in 80%
of all K562 cells indicating apoptotic cell death (Fig. 1A).
Likewise, Jurkat cells were killed with similar e⁄ciency
(data not shown) by GzmB in the presence of SLO, but not
in its absence. A catalytically inactive GzmB variant (Ser195-
Ala) did not induce apoptosis excluding unspeci¢c cytotoxic
e¡ects of the recombinant protein (Fig. 1A). These data
clearly demonstrate that non-glycosylated GzmB is relatively
non-toxic to eukaryotic cells as long as it is not delivered to
the cytosol by membrane-disrupting agents.
To achieve a highly e⁄cient endocytic uptake of recombi-
Fig. 1. Preparation of GzmB and GzmB-CD8. A: Apoptosis induc-
tion by recombinant GzmB. K562 cells were treated with increasing
concentrations of recombinant GzmB and subsequently exposed to
sublytic amounts of SLO (150 ng/ml) for 5 h. Incubation with the
active site mutant GzmBS195A in the presence of SLO and incuba-
tions with GzmB in the absence of SLO (gray bars) served as nega-
tive controls. FITC-annexin V binding records both early apoptotic
(PI negative) and late apoptotic cells, which are PI positive. The di-
agrams (A, C) represent mean values of triplicate measurements
with standard deviations (N.d.: not determined). B: The refolded
proteins MKH6-GzmB and MKH6-GzmB-CD8 (0.5 Wg per lane) be-
fore and after N-terminal trimming by bovine cathepsin C, were an-
alyzed by silver-stained SDS^PAGE. The shift indicates the propep-
tide (MKH6) removal. C: Catalytic activity of recombinant GzmB
and GzmB-CD8. Both enzyme preparations show amidolytic activ-
ities towards a tetrapeptide substrate and are inhibited by recombi-
nant CrmA, which was added at a molar ratio of 1:3 in excess of
GzmB. Hydrolysis of the substrate Ac-IEPD-pNA was determined
by absorption (A) at 405 nm.
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nant non-glycosylated GzmB by membrane targeted delivery,
we selected the disul¢de stabilized Fv fragment (dsFv) of the
monoclonal antibody B3 recognizing the Lewis Y carbohy-
drate antigen [16]. This antigen is highly expressed on the
surface of many breast, colon, lung and epidermal tumor cells
[17] and is endocytosed continuously. B3 antibodies conju-
gated to the PE38 have been approved for a number of clin-
ical trials [18^20]. To ensure a stoichiometric coupling be-
tween GzmB and the dsFv targeting antibody, which carried
a positively charged peptide (R8CP) at the C-terminus of the
Fig. 2. Generation and characterization of immunoconjugates. A:
Schematic representation of B3-PE38 and B3-GzmB. Polyionic
adapter peptides containing a cysteine residue were genetically fused
to the heavy chain C-terminus of the disul¢de-linked dsFv-B3 anti-
body, to the C-terminus of GzmB and to the N-terminus of PE38.
Heterodimeric B3-GzmB conjugates that form via charge^charge in-
teractions are stabilized by an intermolecular disul¢de bond. Ami-
no-termini are indicated by ‘NH2’. B: SDS^PAGE analysis of the
B3-GzmB conjugate and single components under non-reducing
conditions: lane 1, B3-GzmB, 53.8 kDa; lane 2, dsFv-B3-R8C; lane
3, GzmB-CD8. Due to the free C-terminal cysteine residue, both
GzmB-CD8 and B3-R8C exist as monomers and homodimers (upper
band in lanes 2 and 3) after refolding. In addition we analyzed B3-
GzmB under reducing conditions (lane 4). Protein bands were silver
(lanes 1^3) or Coomassie blue stained (lane 4). C: Enzymatic activ-
ity of B3-GzmB in comparison to GzmB and GzmB-CD8. The en-
zymes (100 nM) show similar catalytic activity towards the tetrapep-
tide Ac-IEPD-pNA substrate. Hydrolysis of the substrate was
determined by absorption (A) at 405 nm. Background absorption
was subtracted.
Fig. 3. Characterization of di¡erent cell lines. A: FACS analyses of
cell lines used in this paper. Cells were stained with TexasRed1-la-
beled dsFv-B3. HT-29 cells are shown as negative controls express-
ing no Lewis Y. Our A431 line as well as K562 cells are clearly neg-
ative for dsFv-B3 binding whereas MCF7 and SK-BR3 cells are
positive. B,C: Killing of Lewis Y positive SK-BR3 and Lewis Y
negative A431 cells by GzmB in the presence of sublytic amounts of
SLO. Apoptosis induction by GzmB in the presence of SLO was re-
corded by FACS analysis using FITC-annexin V and PI staining.
Black bars indicate the percentage of viable non-apoptotic cells after
4.5 h of SLO and GzmB exposure, which are both annexin V and
PI negative (N.d.: not determined).
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VH chain [11,12], we fused a negatively charged peptide se-
quence, GCD8, to the C-terminus of the natural GzmB se-
quence (GzmB-CD8, Fig. 1B). Inclusion bodies obtained for
GzmB-CD8 were solubilized, refolded and ¢nally converted to
active GzmB with the help of cathepsin C (Fig. 1B). Fig. 1C
shows that both forms, GzmB and GzmB-CD8, have similar
activities towards the caspase 3-derived peptide substrate Ac-
IEPD-pNA and are inhibited equally well by the cowpox ser-
pin CrmA, indicating that both preparations were correctly
refolded.
The GzmB-CD8 variant was then coupled to the recombi-
nant disul¢de stabilized Fv fragment of B3 via its positively
charged R8CP peptide at the C-terminus of the VH chain
[11,12] (Fig. 2A). In this way, a high yield of the B3-GzmB
immunoconjugate with the expected size of 53.8 kDa was
obtained (Fig. 2B, lane 1). The conjugate split into its three
polypeptide chains upon reduction (Fig. 2B, lane 4). Both
GzmB-CD8 and B3-GzmB showed comparable enzymatic ac-
tivities (Fig. 2C).
To identify suitable sensitive target cells for redirected
GzmB, we analyzed Lewis Y expression and apoptosis induc-
tion by GzmB in the presence of sublytic SLO concentrations.
The A431 cell line derived from a human vulvar squamous
carcinoma, was previously used as a Lewis Y antigen-express-
ing target [17], but the sublines we obtained turned out to be
Lewis Y negative in FACS analyses (Fig. 3A). SK-BR3, a
human breast carcinoma cell line, however, was clearly pos-
itive. To determine the relative sensitivity of these two cell
lines towards apoptosis induction by GzmB, we exposed
SK-BR3 and A431 cells to sublytic amounts of SLO and in-
creasing GzmB concentrations in short-term experiments (Fig.
3B and C). We observed signi¢cant di¡erences in SLO-facili-
tated target cell killing. A431 cells were highly sensitive to
GzmB-induced apoptosis, whereas SK-BR3 cells appeared to
be relatively resistant.
When we incubated the Lewis Y positive cell line SK-BR3
with the B3-GzmB immunoconjugate in the absence of SLO
for 48 h, we observed speci¢c killing of these target cells (Fig.
4A), whereas B3-GzmB displayed no net e¡ect on Lewis Y
negative A431 cells by comparison with untargeted GzmB-
CD8 (Fig. 4B, Table 1). As further Lewis Y positive cell lines,
we used MCF7 cells naturally de¢cient for caspase 3 and
MCF7 cells stably transfected with caspase 3, MCF7casp3
[21]. The caspase 3 positive variant was also speci¢cally killed
by B3-GzmB conjugates, in contrast to the caspase 3 negative
wild-type cells (Table 1) suggesting that the proapoptotic ac-
tion of GzmB was ampli¢ed by caspase 3 in MCF7casp3 cells.
Our experiments clearly show that GzmB retargeted to Lewis
Y positive surface structures can induce cell death without
endosome-disrupting agent. These conjugate-speci¢c e¡ects
occurred at more than 10-fold lower concentrations than re-
quired to generate non-targeted cellular toxicity.
In view of the fact that the Lewis Y-speci¢c B3 antibody
binds to many di¡erent carbohydrate-containing proteins on
the surface of tumors and epithelial cells [17], it is di⁄cult to
envisage how GzmB becomes translocated across the plasma
membrane. After binding of dsFv-B3 to the surface, the com-
plex is internalized via Lewis Y positive receptors and accu-
mulates in endocytic transport vesicles. Due to the lower en-
dosomal pH, GzmB conjugates may dissociate from the
surface antigen and leak into the cytosol inside the cell.
Some of the endocytosed receptor^immunoconjugate com-
plexes may well be translocated into the cytosol [22] and acti-
vate proapoptotic substrates before reaching the proteasomes
for degradation. Our observation that B3-GzmB conjugates
Fig. 4. Biological activity of antibody targeted GzmB. Cytotoxicity
against A: Lewis Y positive SK-BR3 and B: Lewis Y negative
A431 cells by B3-GzmB in comparison to free GzmB-CD8 and tar-
geted B3-PE38 and free E8C-PE38. Cytotoxicity of immunotoxins
and free toxins after 48 h incubation was analyzed by PI staining,
which encompasses late-stage apoptotic and necrotic cells. The num-
ber of unstained (viable) cells was determined by FACS analysis.
Shown is the percentage of viable cells in relation to the average of
viable cells treated with minimal toxin concentrations. Cues repre-
sent single data points, lines show cytotoxic ¢t. The EC50 values
(half-maximal e¡ect concentration) are given in Table 1.
Table 1
Half-maximal e¡ect concentrations for immunotoxins and free tox-
ins
Cell lines Lewis Y EC50 (nM)a
E8C-PE38 B3-PE38 GzmB-CD8 B3-GzmB
A431 Negative 17 14 863 751
K562 37 14 s 1128b s 557b
MCF7 Positive 137c 1.7c 198 140
MCF7casp3 58 1.8 394d 35
SK-BR3 1100 42 1595d 98e
aEC50 indicates the concentration of immunotoxin or free toxin that
shows 50% cytotoxicity towards the cell lines given.
bEC50 not determined, out of range tested.
cDetermined by Kleinschmidt et al. using the same method as pub-
lished [11].
dMean of data obtained from two independent experiments.
eMean of data obtained from three independent experiments.
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and GzmB alone did not display toxicity toward Lewis Y
negative K562 and A431 over a broad range of concentrations
is consistent with a cytosolic proapoptotic function of targeted
GzmB after translocation.
Since it is known that the PE38 fragment in contrast to
GzmB utilizes a cellular mechanism for retrograde entry
into the cytosol [23], we compared the high e⁄cacy of tar-
geted PE38 with that of targeted GzmB under identical con-
ditions. Indeed, B3-PE38 conjugates were e¡ective at 20- and
2-fold lower concentrations than targeted GzmB towards
MCF7casp3 cells and SK-BR3 cells, but unspeci¢c toxicity of
B3-PE38 against Lewis Y negative cells appeared already at
14 nM (Table 1). By contrast, extracellular GzmB-CD8
showed signi¢cantly lower toxicity (EC50 values of 863 nM)
than free E8C-PE38 towards A431 cells (Table 1) despite their
high sensitivity to cytosolic GzmB (Fig. 3C). Conversely, SK-
BR3, a relatively resistant target cell line (Fig. 3B), was killed
with similar e⁄cacy by B3-GzmB in comparison with the B3-
PE38 conjugate. Half-maximal e¡ective concentrations for
both immunoconjugates were at least one order of magnitude
lower than the respective EC50 values of the free toxins. We,
therefore, conclude that dsFv-B3-mediated targeting to Lewis
Y positive cell surface receptors improved the cytosolic uptake
and biological e⁄cacy of GzmB similarly to that of PE38.
In view of these surprising ¢ndings we considered GzmB as
a new surrogate for heterologous toxin components. As one
major concern is the inactivation of human GzmB by extra-
cellular proteinase inhibitors, we investigated its inhibition by
human plasma and K1-AT, a major plasma serine protease
inhibitor of the serpin class. Excess of puri¢ed K1-AT com-
pletely inactivated the neutrophil-derived PR3, but did not
inhibit recombinant GzmB-CD8 (Fig. 5A,B) contradicting
previous ¢ndings [24]. The incubation of GzmB-CD8 in 80%
plasma for 20 min at 37‡C lead to a moderate decrease of
activity of about 30% (Fig. 5A), whereas PR3 was inhibited
by about 70% (Fig. 5B). To exclude the formation of GzmB^
K2-macroglobulin complexes, which still hydrolyze small sub-
strates, but no longer cleave macromolecular substrates, we
analyzed the pro-caspase 7-activating property of recombi-
nant GzmB in the presence and absence of 5% human plasma.
The addition of plasma to recombinant GzmB delayed cleav-
age of the active site mutant pro-caspase 7 insigni¢cantly (Fig.
5C).
Very recently when this work was reviewed, two reports
have been published in which GzmB was similarly used as
an e¡ector domain and fused to targeting sequences [25,26].
GzmB covalently linked to VEGF sequences [25] and to an
antibody fragment (scFvMEL) against a melanoma antigen
[26] was shown to be taken up into the cytosol and was cy-
totoxic towards receptor or antigen-carrying target cells. Hu-
man GzmB is a highly specialized serine protease of lysosome-
like granules with unusual caspase-activating properties and
intrinsic stability in extracellular body £uids and lysosome-
like granules of T and NK cells. Since humans are supposed
to have a strong immunological tolerance against endogenous
GzmB, a humoral or cellular immune response against GzmB
should not occur. In this regard, GzmB is superior to most
other toxins, e.g. Diphtheria toxin, the plant-derived ricin tox-
in A chain or the Pseudomonas exotoxin which are highly
immunogenic [18]. Coupling to other antibodies or receptor
ligands and speci¢c retargeting to receptors that enhance its
endocytic uptake and accumulation should broaden the ap-
plicability and safety of GzmB-based immunoconjugates be-
yond the level of present-day immunotoxins.
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